Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: inferior vena cava filters (IVCF) are widely used to prevent thromboembolic events in patients not suitable for anticoagulation (AC). Although new generations of filters are optional and therefore retrievable, most of them become permanent. Aim of our study was to evaluate real life IVCF management in a tertiary hospital including retrieval rates and reasons for permanent filtering.

Materials And Methods: Electronic charts from patients receiving IVCF in a Swiss university hospital, during 1999-2017, were retrospectively identified. Patients were classified in two groups, according to filter retrieval (RG) or not (NRG). Type and reasons of filter placement were assessed. Retrieval, complications, and mortality rates were calculated. Reasons of non-retrieval were analyzed.

Results: 920 patients received an IVCF during 1999-2017. Filters were retrieved in 372 patients (40.65%). Subjects in the NRG were significantly older, more chronically ill, and presented higher mortality rate at 12 months following filter insertion (29.60% vs. 4.30%; p < 0.001). Reasons for non-retrieval included lack of follow-up (22.34%), persistent contraindications to AC (20.51%), technical issues (17.40%), and severe morbidity with short life expectancy (17.22%). Overall, complication rates after filter placement was 18.58%. Most reported complication was filter thrombosis (15.60%).

Conclusions: In a real life setting, optional IVCF are still too often left in place indefinitely. Need for a systematic follow-up to ensure prompt filter retrieval is warranted. IVCF are not retrieved mostly in chronically and more severely ill patients, likely accounting for higher mortality in these subjects.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2020.01.025DOI Listing

Publication Analysis

Top Keywords

inferior vena
8
vena cava
8
cava filters
8
university hospital
8
patients
5
optional inferior
4
filters
4
filters retrieved?
4
retrieved? real
4
real years
4

Similar Publications

Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.

Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.

View Article and Find Full Text PDF

Background: Achieving R0 resection in hepatopancreatobiliary (HBP) surgery frequently necessitates venous resection and reconstruction. Autologous grafts offer a promising solution, particularly in complex resections where infection risk or graft availability limit the use of synthetic or donor grafts. However, clinical data on the outcomes of autologous venous grafts remain limited.

View Article and Find Full Text PDF

This case underscores the importance of meticulous imaging and procedural vigilance during PCNL to prevent rare complications such as IVC penetration. A prompt multidisciplinary response and careful catheter repositioning ensured a favorable outcome, highlighting strategies to safely manage unexpected vascular injuries during urological procedures.

View Article and Find Full Text PDF

Background And Objective: Surgery of renal cell cancer (RCC) with a caval thrombus (CT) is associated with significant morbidity, particularly regarding thromboembolic complications. There are no data or recommendations regarding the potential benefit of preoperative anticoagulants. We aimed to assess the usefulness of preoperative anticoagulation regarding surgical outcomes and thromboembolic events in patients undergoing nephrectomy with inferior vena cava thrombectomy.

View Article and Find Full Text PDF

Kidney cancer is the 14th most common cancer worldwide. On the basis of the histological characteristics of kidney cancers, most kidney cancers are renal cell carcinomas. Renal leiomyosarcoma (LMS) is extremely rare and malignant and accounts for less than 1% of all kidney cancer cases.

View Article and Find Full Text PDF